The Government is committed to ensuring that patients have access to clinically and cost effective treatments, including those for hepatitis C.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies.
NICE is currently appraising a number of new drugs for use in the treatment of hepatitis C under its technology appraisal process. These are shown in the following table.
Expected date of final guidance
sofosbuvir (Sovaldi) for treating chronic hepatitis C
simeprevir (Olysio) for treating genotype 1 or 4 chronic hepatitis C
ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C
daclatasvir (Daklinza) for treating chronic hepatitis C
ombitasvir/paritaprevir/ritonavir (Viekirax) with or without dasabuvir (Exviera) for treating chronic hepatitis C
More generally, we have launched an Innovative Medicines and Medical Technology Review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.
The review will examine the pathway from ‘first in human’ trials, through licensing and health technology appraisal, to commissioning and clinical practice. It will set out both short and long-term options for action by Government and relevant bodies, including NICE, the Medicines and Healthcare products Regulatory Agency and NHS England, and mark a major contribution to the policy debate.